Telomir Pharms Stock Price, News & Analysis

Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) is a preclinical-stage biotechnology company focused on developing small-molecule therapeutics that target epigenetic and metabolic mechanisms implicated in cancer, aging, and degenerative disease. The company is incorporated in Florida and its common stock is listed on the Nasdaq Capital Market under the symbol TELO, as disclosed in its SEC filings. Telomir’s lead investigational candidate is Telomir-1 (Zn‑Telomir), an oral small molecule being evaluated across multiple preclinical models for its effects on DNA methylation, histone demethylase activity, metal-ion balance, mitochondrial function, and cellular defense pathways.

Core focus and lead program

Across company disclosures and SEC filings, Telomir describes Telomir-1 as a therapy designed to target root epigenetic mechanisms that underlie cancer biology and age-related conditions. In preclinical studies, Telomir-1 has demonstrated activity involving modulation of DNA and histone methylation, restoration of redox balance, and normalization of cellular function. The compound has also been formulated with zinc (Telomir-Zn) to support a controlled intracellular exchange of metal ions, binding excess iron and copper while contributing zinc, which the company notes is relevant to antioxidant defense and DNA stability.

Telomir’s public communications emphasize that Telomir-1 is being advanced through IND-enabling studies with the goal of supporting future first-in-human clinical evaluation, subject to regulatory review. An 8‑K filing details completion of Good Laboratory Practice (GLP) toxicology and safety pharmacology studies in rat and dog models, reporting that Telomir-1 was generally well tolerated with no treatment-related adverse or dose-limiting toxicities observed and consistent systemic exposure after oral administration.

Oncology research and tumor models

Telomir has reported a broad set of preclinical oncology findings for Telomir-1 in company news releases and related 8‑K filings. These include:

• Triple-negative breast cancer (TNBC): In zebrafish tumor xenograft models of aggressive TNBC, Telomir-1 showed statistically significant reductions in primary tumor growth and metastatic dissemination in certain subtypes. In one model with limited responsiveness to paclitaxel, Telomir-1 reduced both tumor size and cancer cell spread, while in another chemotherapy-sensitive model, Telomir-1 produced tumor growth inhibition comparable to paclitaxel as monotherapy, with enhanced effects when combined with paclitaxel. Earlier in vitro work also showed a dose-dependent loss of TNBC cell viability that was reversible by iron re‑addition, supporting an iron-dependent mechanism.
• Prostate cancer: In androgen-responsive human prostate cancer cells (LNCaP), Telomir-1 reduced PSA (prostate-specific antigen) levels in a concentration-related manner and was associated with decreased cellular energy metabolism and viability. In a separate mouse model implanted with aggressive, non‑androgen responsive PC3 prostate cancer cells, Telomir-1 reduced tumor volume as a single agent, and in combination with paclitaxel produced full tumor-volume reduction without treatment-related mortality in the study cohort, whereas paclitaxel alone was associated with mortality. Additional studies in aggressive prostate cancer models have shown that Telomir-1 can reduce DNA hypermethylation of tumor suppressor genes such as MASPIN, RASSF1A, CASP8, and GSTP1, which are involved in invasion control, apoptosis, detoxification, and metastasis.
• Pancreatic cancer: In human pancreatic cancer (PANC‑1) cells, Telomir-1 produced a concentration-dependent reduction in cell survival and mitochondrial activity. The company reports that these effects were partially reversed by iron re‑addition, suggesting involvement of iron-dependent processes along with broader metabolic or epigenetic mechanisms.
• Leukemia: In vitro studies in aggressive human leukemia (HL60) cells showed that Telomir-1 caused a clear, dose-dependent reduction in viable leukemia cells. Company disclosures link these findings to prior work demonstrating Telomir-1’s ability to reduce intracellular iron levels and influence DNA methylation of multiple tumor-suppressor genes.

Epigenetic and metal-ion mechanisms

Telomir’s scientific narrative centers on the intersection of metal homeostasis and epigenetic regulation. In live-cell imaging experiments using human keratinocyte (HaCaT) cells, Telomir-1 produced a strong, time- and dose-dependent reduction of intracellular ferrous iron (Fe²⁺), with greater intracellular iron-lowering activity than the FDA‑approved iron chelator Deferoxamine (DFO) at the same concentrations. Company materials highlight that DFO is known to act primarily in the bloodstream and extracellular space, whereas Telomir-1 was observed to modulate iron levels inside living cells.

Telomir has also reported that Telomir-1 inhibits several families of lysine histone demethylase (KDM) enzymes, including members of the KDM2, KDM5, and KDM6 families. These enzymes are described as important epigenetic regulators of histone methylation, transcription, differentiation, and cellular state. In cancer models, Telomir-1 has been associated with reduced abnormal DNA methylation of tumor-suppressor genes such as STAT1, CDKN2A, MASPIN, RASSF1A, CASP8, GSTP1, and TMS1. Company disclosures state that these genes are linked to immune surveillance, cell-cycle control, apoptosis, detoxification, and metastasis.

According to Telomir’s public statements, Telomir-1’s formulation with zinc is intended to support a controlled intracellular exchange of metal ions, binding excess reactive iron and copper while supplying zinc. The company positions this as a way to influence redox balance and epigenetic enzyme function, with the aim of restoring more normal patterns of gene regulation and mitochondrial performance in preclinical systems.

Aging, degenerative disease, and longevity research

In addition to oncology, Telomir’s communications describe preclinical work in models related to aging biology and age-associated conditions. Across various disclosures, the company states that Telomir-1 has been evaluated in settings involving oxidative stress, mitochondrial dysfunction, and epigenetic drift, which are presented as features of aging and degenerative disease. Examples mentioned in company materials include research in models of accelerated aging, age-related disease pathways, and metabolic dysfunction, though these are characterized as preclinical and exploratory.

Telomir’s broader positioning, including in its Polygon description, frames the company as seeking to address underlying biological mechanisms rather than only downstream symptoms. This includes references to telomere biology, epigenetic drift, and metal-ion imbalance as interconnected contributors to cellular aging and disease processes. The company’s disclosures emphasize that Telomir-1 remains in preclinical development and that any potential applications in aging or degenerative disease would be subject to further research and regulatory review.

Corporate structure, listing, and geography

SEC filings identify Telomir Pharmaceuticals, Inc. as a corporation organized under the laws of Florida, with principal executive offices in Miami, Florida. The company’s common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and trades on The Nasdaq Stock Market LLC under the ticker TELO. An 8‑K filed in January 2026 notes that Nasdaq notified the company of non‑compliance with the annual meeting requirement under Nasdaq Listing Rule 5620(a), and that Telomir intends to submit a plan to regain compliance and hold its annual meeting following SEC review of its proxy materials. The notice did not result in immediate delisting and did not have a current effect on trading of the company’s common stock, according to that filing.

Intellectual property and global rights to Telomir-1

In October 2025, Telomir announced, and subsequently reported in an 8‑K, that it entered into a binding Letter of Intent (LOI) to acquire TELI Pharmaceuticals, Inc. through a stock‑for‑stock transaction. The stated purpose of this transaction is to consolidate worldwide intellectual property and development rights to Telomir-1 within a single public company structure. Company communications describe this as aligning U.S. and ex‑U.S. rights and creating a unified owner of the global Telomir-1 portfolio, subject to completion of definitive agreements, shareholder approvals, and other customary conditions.

The LOI also contemplates potential cash contributions from certain TELI shareholders tied to development milestones, including IND acceptance and initiation of a Phase 1/2 study, with related equity allocation terms described in the filing. Telomir presents this transaction as a way to support future development, partnership, and licensing strategies for Telomir-1 across oncology and age-related disease indications.

Development stage and regulatory pathway

Across its news releases and SEC filings, Telomir consistently characterizes itself as a preclinical-stage biotechnology company. The company reports that it is conducting IND-enabling activities for Telomir-1, including GLP toxicology, safety pharmacology, and multiple preclinical efficacy and mechanistic studies. An 8‑K filed in December 2025 states that the company views completion of IND-enabling GLP safety studies as a key milestone in its clinical development strategy and indicates that Telomir is preparing an Investigational New Drug (IND) application for submission to the U.S. Food and Drug Administration, with the timing described as subject to regulatory review and other factors.

Telomir’s disclosures emphasize that all Telomir-1 data reported to date are preclinical, generated in vitro or in animal models, and that advancement into human studies will depend on regulatory clearance. The company also notes that it is preparing scientific manuscripts and conference abstracts to present its findings to the broader scientific and clinical research community.

Business model and sector positioning

Based on its public statements, Telomir’s business model is centered on the discovery and development of small-molecule epigenetic therapies with potential applications in oncology and age-related disease. The company highlights Telomir-1 as its lead asset and describes efforts to strengthen its intellectual property position and global rights to that compound. Telomir operates within the biotechnology industry and the healthcare sector, with a focus on preclinical research, regulatory preparation, and potential future clinical development and partnering opportunities.

Risk and forward-looking considerations

Telomir’s press releases and SEC filings include cautionary language noting that statements about future development plans, regulatory submissions, clinical trials, and potential indications are forward-looking and subject to risks and uncertainties. The company underscores that preclinical results may not predict clinical outcomes and that regulatory, scientific, and market factors could affect the progression of Telomir-1 or any other programs. Investors and readers are directed in those documents to consider the limitations of preclinical data and the inherent uncertainty of early-stage biotechnology development.

FAQs about Telomir Pharmaceuticals (TELO)

• What does Telomir Pharmaceuticals do?
  Telomir Pharmaceuticals is a preclinical-stage biotechnology company developing small-molecule therapeutics that target epigenetic and metabolic mechanisms underlying cancer, aging, and degenerative disease. Its lead candidate, Telomir-1, is being studied in preclinical models for effects on DNA methylation, histone demethylases, metal-ion balance, and cellular defense pathways.
• What is Telomir-1?
  Telomir-1 (also referred to as Zn‑Telomir) is Telomir’s lead investigational small molecule. Company disclosures describe it as an oral compound that has shown activity in preclinical studies involving modulation of DNA and histone methylation, reduction of intracellular iron, inhibition of certain histone demethylases, and normalization of redox and mitochondrial measures in various cell and animal models.
• Which diseases is Telomir-1 being studied for?
  According to Telomir’s news releases and 8‑K filings, Telomir-1 is being evaluated preclinically in oncology models including triple-negative breast cancer, prostate cancer, pancreatic cancer, and leukemia. The company also references research in aging biology and age-related disease settings, describing a broader focus on conditions linked to epigenetic dysregulation and metal-ion imbalance.
• What stage of development is Telomir-1 in?
  Telomir states that it is a preclinical-stage company and that Telomir-1 is in the IND-enabling phase. The company has reported completion of GLP toxicology and safety pharmacology studies and ongoing preclinical efficacy and mechanistic work, with plans to submit an Investigational New Drug application subject to regulatory review.
• How does Telomir-1 relate to iron and other metals?
  Company data show that Telomir-1 reduces intracellular ferrous iron levels in human cell models and has been formulated with zinc to support a controlled exchange of metal ions. Telomir links this activity to modulation of iron-dependent epigenetic enzymes and oxidative stress pathways, which it presents as relevant to both cancer and aging biology in preclinical systems.
• On which exchange does TELO trade?
  SEC filings state that Telomir Pharmaceuticals’ common stock is listed on The Nasdaq Stock Market LLC under the ticker symbol TELO.
• Where is Telomir Pharmaceuticals based?
  Telomir’s SEC filings identify the company as a Florida corporation with principal executive offices located in Miami, Florida.
• What is the significance of the TELI Pharmaceuticals LOI?
  Telomir has entered into a binding Letter of Intent to acquire TELI Pharmaceuticals, Inc. through a stock-for-stock transaction. The company describes this as a way to consolidate worldwide intellectual property and development rights to Telomir-1 within a single public company, subject to completion of definitive agreements and approvals.
• Has Telomir-1 been tested in humans?
  Based on the company’s disclosures and SEC filings, Telomir-1 remains in preclinical development. The company reports that it is preparing an IND submission and that no first-in-human clinical studies have yet been initiated.
• What kinds of risks does Telomir highlight in its disclosures?
  Telomir’s filings and press releases note that statements about future development, regulatory milestones, and potential indications are forward-looking and subject to risks and uncertainties. They emphasize that preclinical results may not translate to clinical benefit and that regulatory, scientific, and financial factors could affect the company’s plans.